Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations
October 19, 2023
Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables
Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – Tampere University Hospital’s (Finland) environmental sustainability, including a deep assessment of the interventional cardiology space and evaluation of its carbon footprint. The results of the analysis have been translated into a joint action plan that will help Heart Hospital accelerate its decarbonization efforts in line with Finland’s world-leading commitment to reach net zero emissions by 2035.
“Sustainability is an integral part of Tampere Heart Hospital strategy. We are aware that hospitals generate a significant amount of waste daily and consume a lot of energy. We want to contribute to the development of environmental responsibility in healthcare,” said Pasi Lehto CEO and Chief Medical Officer at Heart Hospital.
“We want to ascertain where we are now and how we can further accelerate our transition towards net zero,” said Aki Haukilahti, CFO at Tampere Heart Hospital. “Our long-standing relationship with Philips and their industry leadership in driving sustainable healthcare made them a natural partner to help audit our emissions and develop a roadmap for the future.”
Part of an existing 15-year strategic managed services agreement between Heart Hospital and Philips, the analysis involved a detailed lifecycle assessment of the hospital’s medical equipment, supply chain, and clinical operations. The analysis provided a baseline carbon footprint for Tampere Heart Hospital’s interventional cardiology service and facilitated the identification of opportunities to enhance patient throughput and equipment utilization to reduce future emissions. Top findings included optimization of the hospital’s patient care pathways to improve efficiency and materials use, and opportunities for reducing inbound airfreight, reducing waste and improving waste separation.
“At Philips, we are committed to driving systemic change towards more sustainable and equitable patient care. Through our healthcare technology and expertise, we can help healthcare providers to support their patients with as little impact on the environment as possible,” said Robert Metzke, Global Head of Sustainability at Philips. “This valuable and informative analysis with Tampere Heart Hospital, a pioneering and leading global cardiac care provider, will help achieve our shared goal of taking care of patients and the planet at the same time.”
In addition to a detailed analysis of carbon emissions associated with the hospital’s medical equipment and supply chain, Philips’ analysis of the hospital’s current emissions also encompasses clinical operations in key patient care pathways.
This sustainability program with Tampere Heart Hospital follows similar analyses conducted by Philips earlier in 2023 at Vanderbilt University Medical Center (Nashville, USA) and the private biomedical research and clinical care provider Champalimaud Foundation (Lisbon, Portugal), aimed at reducing the carbon footprint of their diagnostic imaging.
Globally, healthcare systems have a significant climate footprint and make a major contribution to the climate crisis . Building on decades of experience reducing energy consumption, waste, and materials and substance usage, Philips has operated globally carbon-neutral since 2020, embedding EcoDesign principles and circular business models into its innovation processes and ways of working. The company offers a range of health technologies and innovations that help reduce healthcare providers’ impact on the environment. For example, its Philips Spectral CT 7500 uses 62.5% less energy , and the Philips MR – Ingenia Ambition 1.5T, which uses a breakthrough design where the magnetic components are completely sealed and only need seven liters of helium over its lifetime compared to roughly 1,500 liters with other Philips systems . Additionally, with Philips MR SmartSpeed, the Ingenia Ambition 1.5T uses up to 53% less power per patient scan .
Read more here on how Philips is partnering with hospitals around the world to drive sustainable healthcare.
 When compared to an equivalent CT model of one of the industry leaders
 Applicable to Ambition S. Philips SmartSpeed power consumption versus Philips SENSE based scanning. Based on COCIR and in-house simulated environment. Results can vary based on site conditions.
For further information, please contact:
Philips Global Press Office
Tel: +31 6 10 55 8116
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release
The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s
AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release
Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.firstname.lastname@example.org
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release
ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi
ForFarmers N.V.: Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o.6.12.2023 10:30:00 CET | Press release
Lochem, 6 December 2023 Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o. Today, ForFarmers received approval from the Polish competition authority to acquire Piast Pasze Sp. z.o.o. ("Piast"). With this transaction, announced on 25 July 2023, ForFarmers/Tasomix's volume in Poland will expand by 410,000 tonnes, strengthening its position in the broiler sector in particular. Parties will work towards a closing of the acquisition. This transaction is in line with ForFarmers/Tasomix's strategic objectives to expand in the attractive Polish agricultural market. This press release contains information that qualifies as inside information within the meaning of Article 7 paragraph 1 of the EU Market Abuse Regulation. Note to the editor / For further information: Floor van Maaren, T: 06-29597746 Paweł Świerkula, Managing Director ForFarmers/Tasomix M + 48 510 22 00 22 • E: email@example.com About ForFarmers ForFarmers N.V. is an international organisation tha
Resultat af auktion over 1,75 pct. Danske Stat 2025 og 2,25 pct. Danske Stat 20336.12.2023 10:26:31 CET | pressemeddelelse
Bud, salg, skæringspris, pro rata og effektiv rente fremgår af nedenstående oversigt: ISINBud mio. kr. (nominelt)SalgSkæringskursPro-rataEffektiv rente, pct. p.a.99 23138 1,75% 15/11/20251.8601.10098,34100 %2,6499 24532 2,25% 15/11/2033300 300 97,80100 %2,50I alt2.1601.400 Salget bliver afviklet den 8. december 2023.